ChromaDex Corporation (CDXC) News
Filter CDXC News Items
CDXC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CDXC News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CDXC News From Around the Web
Below are the latest news stories about CHROMADEX CORP that investors may wish to consider to help them evaluate CDXC as an investment opportunity.
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025LOS ANGELES, January 06, 2025--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. |
US Stocks That May Be Priced Below Intrinsic Value In January 2025As the United States stock market enters 2025, major indices like the Dow Jones and S&P 500 are attempting to recover from a sluggish start, following a challenging end to 2024. In such conditions, identifying stocks that may be priced below their intrinsic value can offer potential opportunities for investors looking to capitalize on market inefficiencies. |
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDexADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog. |
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to GrowHere, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025. |
3 US Growth Companies With High Insider Ownership Expecting Up To 119% Earnings GrowthAs the U.S. stock market navigates a landscape marked by cautious optimism following a benign inflation reading, investors are closely monitoring potential volatility amid ongoing economic developments and policy decisions. In this context, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those closest to the business and may offer robust earnings potential despite broader market uncertainties. |
Exploring December 2024's US Undervalued Small Caps With Insider BuyingOver the last 7 days, the United States market has experienced a 3.5% drop, yet it has shown resilience with a 22% rise over the past year and projected earnings growth of 15% per annum in the coming years. In this context, identifying stocks that are potentially undervalued can be crucial for investors seeking opportunities amidst fluctuating market conditions, particularly when insider buying suggests confidence from those closest to the company. |
Even though ChromaDex (NASDAQ:CDXC) has lost US$73m market cap in last 7 days, shareholders are still up 389% over 1 yearIt's been a soft week for ChromaDex Corporation ( NASDAQ:CDXC ) shares, which are down 13%. But that isn't a problem... |
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products CategoryLOS ANGELES, December 03, 2024--ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made an impact on their industries and society at large. |
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
3 US Stocks Estimated To Be Trading At Discounts Ranging From 13% To 41%In the midst of geopolitical tensions and fluctuating market indices, the U.S. stock market is experiencing a cautious sentiment as investors react to recent earnings reports and global developments. Despite these uncertainties, opportunities may arise for discerning investors who focus on identifying stocks that are potentially undervalued, offering a chance to invest in companies trading at significant discounts relative to their intrinsic value. |